How An Adaptive Weight-Loss Strategy Benefits Breast Cancer Survivors

Obesity affects more than one in three breast cancer survivors, significantly increasing the risk of cancer recurrence, cardiovascular disease, poorer quality of life, and premature death. While lifestyle modifications are the foundation of weight management, many survivors struggle to achieve sufficient weight loss through diet and exercise alone.

A clinical trial published in Clinical Cancer Research demonstrated that a personalized, adaptive treatment strategy can help breast cancer survivors achieve clinically meaningful weight loss. The phase II Adaptive Nutrition and Exercise Weight Loss (A-NEW) trial (NCT04499950) evaluated whether assessing early response to a behavioral weight loss (BWL) program can identify patients who require pharmacotherapy augmentation. The study suggests that instead of a one-size-fits-all approach, clinicians can successfully tailor obesity care based on early progress.

Key Takeaways for Oncology Nurses

• The Clinical Need: Over half of breast cancer survivors gain weight post-diagnosis. A weight loss of 5% is the clinical benchmark associated with metabolic improvements and reduced recurrence risk.
• Early Nonresponse is Common: Nearly 72% of survivors did not achieve a 5% weight loss after two months of lifestyle modifications alone.
• Adaptive Medication Works: Adding naltrexone/bupropion (Contrave) for early nonresponders helped 42.1% achieve clinically meaningful weight loss by six months.
• Drug Interaction Alert: Bupropion is a potent CYP2D6 inhibitor. Patients taking tamoxifen must be excluded because bupropion can reduce tamoxifen's efficacy.
• Demographic Disparities: Black, younger, and premenopausal survivors are more likely to experience slower initial weight loss, highlighting the need for tailored support.

Study Design and Methodology

Led by Jennifer Y. Sheng, MD, assistant professor of oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, the prospective, single-arm A-NEW trial enrolled overweight or obese women with prior stage 0–III breast cancer. Participants initiated a six-month BWL program adapted from the POWER-remote study, featuring remote coaching, dietary modifications, and calorie/exercise tracking via a Fitbit.

After two months, progress was evaluated:

• Fast Responders (FAST-BWL): Lost at least 5% of baseline weight and continued with the lifestyle program alone.
• Slow Responders (SLOW-BWL): Lost less than 5% of baseline weight and were prescribed oral naltrexone/bupropion while continuing lifestyle therapy.

Of the 53 evaluable participants at two months, 71.7% (n=38) were slow responders, while 28.3% (n=15) were fast responders.

Efficacy and Cardiometabolic Outcomes

In the intent-to-treat analysis, 42.1% (16 of 38) of the slow responders achieved at least 5% weight loss by six months. For those who completed the full trial (per-protocol), 50% (16 of 32) of slow responders met the target. By six months, the SLOW-BWL group achieved a total mean weight loss of 5.1%, while the FAST-BWL group achieved 10.8%.

Beyond weight reduction, the study demonstrated substantial clinical benefits:

• Symptom Improvement: Achieving at least 5% weight loss was associated with significant patient-reported improvements in physical function and pain reduction.
• Cardiometabolic Risk Factors: Slow responders on combination therapy experienced significant baseline-to-six-month improvements in hemoglobin A1c and fasting triglyceride levels.

Safety, Side Effects, and Nurse Monitoring

The oral combination medication was generally well-tolerated, with only one participant discontinuing the trial due to medication-related adverse events. There were no serious (grade 3 or higher) adverse events.

However, mild-to-moderate side effects were common in the SLOW-BWL group. Oncology nurses should counsel patients to anticipate and monitor for:

• Gastrointestinal Symptoms: Constipation (52.6%), nausea (42.1%), dry mouth (36.8%), and abdominal pain (18.4%).
• Other Common Side Effects: Insomnia (31.6%), headache (23.7%), fatigue (21.1%), and anxiety (15.8%).

Dose reductions were advised for 9 participants, and 4 required temporary drug interruptions before successfully resuming therapy.

Addressing Disparities in Care

The A-NEW study revealed that Black participants, younger women, and premenopausal women were significantly more likely to experience slower initial weight loss, making up a larger portion of the slow-responder cohort. Only 33% of Black participants in the SLOW-BWL group achieved the 5% target compared to 46% of White participants.

Oncology nurses can bridge these gaps by:

• Conducting early, proactive assessments to better understand and address barriers to successful weight management in these populations.
• Implementing culturally tailored nutrition counseling and exercise support to augment weight loss in Black and younger patients.
• Advocating for personalized, multi-targeted interventions rather than relying solely on self-directed lifestyle modifications.

References

1. Johns Hopkins Study Supports Personalized Weight-Loss Care for Breast Cancer Survivors. Johns Hopkins Medicine Newsroom. Published August 17, 2026.
2. Sheng JY, Zahurak M, Too F, et al. Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight loss (A-NEW) Study. Clin Cancer Res. Published online August 4, 2026. doi:10.1158/1078-0432.CCR-26-0270